Literature DB >> 18241252

Independent predictors of metachronous bladder transitional cell carcinoma (TCC) after nephroureterectomy for TCC of the upper urinary tract.

Giacomo Novara1, Vincenzo De Marco, Orietta Dalpiaz, Fedra Gottardo, Vianney Bouygues, Antonio Galfano, Guido Martignoni, Jean Jacques Patard, Walter Artibani, Vincenzo Ficarra.   

Abstract

OBJECTIVE: To identify the prognostic factors predictive of metachronous bladder transitional cell carcinoma (TCC) in a multi-institutional dataset of patients who had undergone nephroureterectomy (NU) for nonmetastatic upper urinary tract (UUT) TCC. PATIENTS AND METHODS: The clinical and pathological data of 231 patients who had had NU for UUT-TCC from 1989 to 2005 in three European centres were collected retrospectively, and analysed for clinical and pathological variables.
RESULTS: The median follow-up was 38 months; during the follow-up, bladder TCC was detected in 109 patients (47.2%), and was significantly more common in patients who had UUT-TCC after previous bladder TCC (P < 0.001), in those with ureteric cancer (P = 0.022), and in those with pT2 UUT-TCC (P = 0.017). On multivariate analysis, a previous history of bladder TCC was the only independent predictor of metachronous bladder TCC (hazard ratio 2.825; P < 0.001). The 5-year probability of being free from metachronous bladder TCC was 45.5%. A history of bladder TCC (P < 0.001) and UUT tumour site (P = 0.01) were significantly associated with the probability of bladder recurrence-free survival. On multivariate analyses, a previous history of bladder TCC (hazard ratio 2.226; P < 0.001) and the presence of ureteric TCC (1.562; P = 0.036) were independent predictors of the probabilities of being free from metachronous bladder TCC.
CONCLUSION: In this multi-institutional study of patients who had had NU for UUT-TCC, a history of bladder TCC was the only independent predictor of metachronous bladder TCC, while both a history of bladder TCC and the presence of ureteric tumours were predictive of the probabilities of being free from metachronous bladder TCC.

Entities:  

Mesh:

Year:  2008        PMID: 18241252     DOI: 10.1111/j.1464-410X.2008.07438.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  18 in total

Review 1.  Optimal Management of Upper Tract Urothelial Carcinoma: an Unmet Need.

Authors:  Mounsif Azizi; Salim K Cheriyan; Charles C Peyton; Beat Foerster; Shahrokh F Shariat; Philippe E Spiess
Journal:  Curr Treat Options Oncol       Date:  2019-04-01

2.  [Surgical management for upper urinary tract transitional cell carcinoma].

Authors:  S Schmidt; A Spek
Journal:  Urologe A       Date:  2015-08       Impact factor: 0.639

3.  Intravesical recurrence after radical nephroureterectomy for upper tract urothelial carcinomas: predictors and impact on subsequent oncological outcomes from a national multicenter study.

Authors:  Evanguelos Xylinas; Pierre Colin; François Audenet; Véronique Phe; Luc Cormier; Olivier Cussenot; Alain Houlgatte; Gilles Karsenty; Franck Bruyère; Thomas Polguer; Alain Ruffion; Antoine Valeri; François Rozet; Jean-Alexandre Long; Marc Zerbib; Morgan Rouprêt
Journal:  World J Urol       Date:  2012-09-30       Impact factor: 4.226

Review 4.  Simultaneous en-bloc robot-assisted radical cystectomy and nephro-ureterectomy: technique description, outcomes, and literature summary.

Authors:  Stephan Buse; Carolin Eva Hach; Assen Alexandrov; Rene Mager; Axel Haferkamp
Journal:  J Robot Surg       Date:  2016-05-06

5.  Early repeated ureteroscopy within 6-8 weeks after a primary endoscopic treatment in patients with upper tract urothelial cell carcinoma: preliminary findings.

Authors:  Luca Villa; Jonathan Cloutier; Julien Letendre; Achilles Ploumidis; Andrea Salonia; Jean-Nicolas Cornu; Francesco Montorsi; Olivier Traxer
Journal:  World J Urol       Date:  2015-12-23       Impact factor: 4.226

6.  Optimal body mass index cut-point for predicting recurrence-free survival in patients with non-muscle-invasive urothelial carcinoma of bladder.

Authors:  Satoru Yonekura; Fumihito Terauchi; Kenji Hoshi; Takehiko Yamaguchi; Shigeo Kawai
Journal:  Oncol Lett       Date:  2018-07-04       Impact factor: 2.967

7.  Aristolochic acid-containing Chinese herbal medicine and upper urinary tract urothelial carcinoma in Taiwan: a narrative review.

Authors:  Kathleen G Dickman; Chung-Hsin Chen; Arthur P Grollman; Yeong-Shiau Pu
Journal:  World J Urol       Date:  2022-07-22       Impact factor: 3.661

8.  The neutrophil-to-lymphocyte ratio as a predictor of intravesical recurrence in patients with upper urinary tract urothelial carcinoma treated with radical nephroureterectomy.

Authors:  Nozomu Kishimoto; Tetsuya Takao; Sohei Kuribayashi; Gaku Yamamichi; Kosuke Nakano; Masataka Kawamura; Koichi Tsutahara; Go Tanigawa; Seiji Yamaguchi
Journal:  Int J Clin Oncol       Date:  2016-09-10       Impact factor: 3.402

9.  Predictive value of clinicopathological markers for the metachronous bladder cancer and prognosis of upper tract urothelial carcinoma.

Authors:  Chenchen Feng; Lujia Wang; Guanxiong Ding; Qiang Ding; Zhongwen Zhou; Haowen Jiang; Zhong Wu
Journal:  Sci Rep       Date:  2014-02-06       Impact factor: 4.379

10.  Predictors of intravesical recurrence after radical nephroureterectomy for upper urinary tract urothelial carcinoma: an inflammation-based prognostic score.

Authors:  Yang Hyun Cho; Young Ho Seo; Seung Jun Chung; Insang Hwang; Ho Song Yu; Sun-Ouck Kim; Seung Il Jung; Taek Won Kang; Dong Deuk Kwon; Kwangsung Park; Jun Eul Hwang; Suk Hee Heo; Geun Soo Kim; Eu Chang Hwang
Journal:  Korean J Urol       Date:  2014-07-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.